Frontage Holdings IPO: Risk-Reward Is Favourable at the Low-End of Price Range
Frontage Holdings (1521 HK) has launched its Hong Kong IPO at a price range of HK$2.55-3.20 per share to raise HK$1.27-1.60 billion ($160-200...
763 Views
Frontage Holdings (方达控股) IPO: Reasonable Valuation & Quality Cornerstones
Frontage Holdings, a pre-clinical CRO arm of A-share listed Hangzhou Tigermed Consulting (300347 CH), started book building today to raise up to...
789 Views
ECM Weekly (11 May 2019) - AB InBev APAC, ELuckin, Aakash Edu, GSX Techedu, CSSC (HK) Shipping
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
573 Views
Frontage Holdings IPO Preview: An Uncertain Transition
Frontage Laboratories Inc (1000371Z HK) is a global contract research organisation (CRO) which is backed by Hangzhou Tigermed Consulting (300347...
671 Views
Viva Biotech (维亚生物) IPO: Warning Signs from 2018 Numbers (Part 2)
Viva Biotechnology, a China-based drug discovery company, is seeking to raise USD 200m to list on the Hong Kong Stock Exchange. It has recently...
793 Views